Management of advanced prostate cancer with germline or somatic ...
Jun 11, 2025 · Accumulating data have shown that males with metastatic castration-resistant prostate cancer (mCRPC) and a pathogenic variant in a HRR gene may respond to treatment with a PARP …
June Prostate Cancer Highlights: Top 5 Updates Patients Should Know
Jun 27, 2025 · FDA Updates Treatment Label for HRR+ Metastatic Prostate Cancer In June 19, Talzenna (talazoparib) plus Xtandi (enzalutamide) received a label update from the FDA for men with …
Genetic testing for homologous recombination repair (HRR) in …
Patients with metastatic castration-resistant prostate cancer (mCRPC) have an average survival of only 13 months. Identification of novel predictive and actionable biomarkers in the homologous …
Treatment patterns and outcomes in metastatic castration-resistant ...
Feb 26, 2024 · Abstract Background Although germline BRCA mutations have been associated with adverse outcomes in prostate cancer (PC), understanding of the association between …
Impact of BRCA alterations on androgen receptor pathway inhibition ...
May 28, 2025 · Alterations in homologous recombination repair (HRR) pathways, found in approximately a quarter of metastatic PCas, are associated with adverse outcomes. We sought to understand how …
Advances in Targeted Therapy for Metastatic Prostate Cancer
Apr 29, 2025 · Over the past few years, treatment for advanced prostate cancer has begun shifting away from a one-size-fits-all approach toward biomarker-based therapies for select groups of patients. …
Homologous recombination repair status in metastatic prostate cancer …
Feb 5, 2025 · Arce-Gallego et al. integrate next-generation sequencing with a RAD51 immunofluorescence assay to assess HRR function in advanced prostate cancer. They link RAD51 …
ASCO 2025: Parp Up the Volume!: Combination Strategies in Advanced ...
ASCO 2025 Combination Strategies in Advanced Prostate Cancer, PARP inhibitors, homologous recombination repair (HRR) mutations, AMPLITUDE Trial.
Double-Strand Breaks1 These genes are associated with development and progression of prostate cancer1 Patients with prostate cancer and certain HRR gene mutations (BRCA1, BRCA2, or ATM) …
First-line talazoparib with enzalutamide in HRR-deficient metastatic ...
Dec 4, 2023 · Recent approvals of new treatments have led to improved outcomes for patients with advanced prostate cancer 1,2. However, metastatic disease remains aggressive and progression is …